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Acute lymphoblastic leukemia (ALL) is a heterogeneous group of hematologic malignancies that arise from clonal proliferation of immature lymphoid cells in the bone marrow, peripheral blood and other organs. 1 T-cell acute lymphoblastic leukemia (T-ALL) is characterized by outgrowth of immature T cells. 1 Gain-of-function mutations in NOTCH1 are common in T-ALL, 2 making this receptor a promising target for drugs such as γ-secretase inhibitors (GSIs), which can block a proteolytic cleavage required for NOTCH1 activation. 3 However, the enthusiasm for these therapies has been tempered by tumor resistance and paucity of information on the oncogenic programs regulated by oncogenic NOTCH1. 3, 4 Therefore, the purpose of this study was to identify oncogenic NOTCH1-mediated molecular and genetic changes that contribute to T-ALL for future targeted therapies in order to improve leukemia treatment.
The phosphatase of regenerating liver (PRL) family of phosphatases, consisting of PRL1, PRL2 and PRL3, represents an intriguing group of proteins that are currently being validated as potential biomarkers and therapeutic targets in human cancer, including breast cancer, ovarian cancer and lung cancer. 5 Notably, recent findings indicate that PRLs have important roles in the pathogenesis of hematological malignancies. 6 For instance, PRL3 is highly expressed in BCR-ABL-positive ALL, which may be responsible for the aggressive phenotype of the disease.
7 PRL2 is located on human chromosome 1p35, a region often rearranged or amplified in malignant lymphoma and B-cell chronic lymphocytic leukemia (B-CLL).
5 PRL2 mRNA is also highly expressed in primary human acute myeloid leukemia (AML) and T-ALL cells, suggesting that PRL2 may play an important role in the pathogenesis of T-ALL. 8, 9 We recently generated Prl2-deficient mice and found that PRL2 is required for extra-embryonic development by negatively regulating PTEN, thereby activating the PI3K-Akt pathway. 10 In a previous study, we observed that PRL2 enhances hematopoietic stem and progenitor cell (HSPC) proliferation through mediating SCF/KIT signaling. 11 These findings suggest that PRLs may represent novel therapeutic targets for the treatment of hematological malignancies. [6] [7] [8] [9] [10] [11] To determine the functional requirement for PRL2 in the pathogenesis of T-ALL, we analyzed PRL2 expression in a gene expression profiling dataset reported by Haferlach et al. 9 We found that PRL2 is highly expressed in both human B-ALL and T-ALL Accepted article preview online 22 November 2016; advance online publication, 9 December 2016 patient cells compared with normal control cells (Figure 1a ). Given that PRL2 is important for the proliferation and survival of hematopoietic stem and progenitor cells, 11 we determined the effect of genetic inhibition of PRL2 on human T-ALL cell proliferation by introducing shRNA targeting PRL2 into human T-ALL cells using lentiviruses. We found that knockdown of PRL2 decreased the proliferation and survival of human T-ALL cells (Figures 1b and c; Supplementary Figures S1a and b) . We also found that ectopic expression of a dominant-negative PRL2 mutant (PRL2-CSDA) decreased the proliferation of Molt4 cells compared with mock transduced cells (Supplementary Figure S1c) . 12 In a previous study, we conducted a computer-based virtual screen and identified several compounds capable of inhibiting PRL activity. 13 The lead compound (Cmpd-43) displayed a respectable pharmacokinetic profile in mouse with a plasma compound exposure C max = 0.3 mM and a half-life t 1/2 = 15.8 h at a single 20 mg/kg intraperitoneal dosage. Intraperitoneally injection of 15 mg/kg of PRLi daily for 3 weeks exhibited no toxicity, and body weight and weights of major organs (liver, spleen and kidney) were comparable to control mice. 13 We named the compound Cmpd-43 as PRL inhibitor (PRLi). To determine the effect of pharmacological inhibition of PRL2 on human T-ALL cells, we treated several human T-ALL cell lines with PRLi and measured cell viability. We found that pharmacological inhibition of PRL2 activity decreased proliferation and enhanced apoptosis in a dosage-dependent manner (Figures 1d and e ). PRLi appears to be specific to leukemia cells and does not affect the viability of human cord blood mononuclear cells and HSPCs (Supplementary Figures S1d-f). Given that PRLi specifically blocks PRL1-induced cell proliferation and migration through attenuation of both ERK1/2 and AKT activity, 13 we treated two human T-ALL cell lines with PRLi and then measured the level of phosphorylated ERK using western blot analysis. We found that PRLi treatment resulted in decreased ERK phosphorylation in both Loucy and CEM cells (Figure 1f ), suggesting that PRLi can inhibit ERK activation in leukemia cells. These results demonstrate that PRL2 is important for the proliferation and survival of human T-ALL cells.
More than 90% of human T-ALL show signs of constitutive NOTCH1 pathway activation and majority of human T-ALL cell lines are addicted to NOTCH1 function. 4 Indeed, we found that PRL2 is a direct target of NOTCH1 signaling in mouse T-cell progenitors (MK and YL unpublished data). In order to test whether PRL2 is important for oncogenic NOTCH1-induced T-ALL in vivo, we transduced lineage -bone marrow progenitors from wild-type and Prl2 null mice with retrovirus encoding the constitutively active intracellular domain of NOTCH1 (NOTCH1-ICN1-EGFP). These cells were then transplanted into lethally irradiated recipient mice, and we monitored for the presence of CD4 + CD8
+ double-positive (DP) leukemic cells in the peripheral blood. 14 We found that the peripheral blood of control animals contained high number of donor-derived CD4 + CD8 + DP cells at 5 and 7 weeks after transplantation, while only a minute number of leukemic cells were observed in recipient of Prl2 null cells (Figure 2a ). The development of T-ALL in host that received wild-type cells transduced with NOTCH1-ICN1 retrovirus was rapid, with all control animals succumbing to the disease and died 9 weeks following transplantation (Figure 2b ). In contrast, animals repopulated with Prl2 null cells displayed significant protection from disease, with majority of animals remaining disease-free 18 weeks following transplantation (Figure 2b ). All control animals show enlarged spleen compared with recipient mice repopulated with PRL2 null cells (Figure 2c and Supplementary Figure S2a) .
Prl2
−/− cells expressing NOTCH1-ICN1 showed long-term myeloid cell, B cell, CD4
+ and CD8 + T-cell engraftment in the surviving recipients (Supplementary Figure S2b) . These results demonstrate that PRL2 is essential for the initiation and/or maintenance of T-ALL induced by oncogenic NOTCH1.
To determine whether PRL2 is essential for T-ALL maintenance, we introduced NOTCH1-ICN1 into Prl2 +/+ and Prl2 −/− fetal liver While most recipient mice repopulated with Prl2 +/+ cells expressing NOTCH1-ICN1 developed leukemia and died within 40 days, none of the recipient mice repopulated with Prl2 −/− cells developed leukemia (Figure 2f) . Further, LICs were not detectable in the spleen of recipient mice repopulated with Prl2 −/− LICs (Figure 2g ). It appears that PRL2 is important for the ability of LICs, defined immunophenotypically by flow cytometry, to recapitulate leukemia in secondary hosts rather than maintaining the number of LICs. Thus, these data demonstrate that PRL2 is important for the maintenance of T-ALL mediated by oncogenic NOTCH1.
DELTA/ NOTCH1 association is one of the most important signals provided by the thymic environment to initiate T-cell differentiation. 16 Given that NOTCH1 signaling upregulates c-Kit expression in early T-cell progenitors (ETPs) (MK and YL unpublished data), we hypothesized that PRL2 may promote the pathogenesis of T-ALL through maintaining c- Figure S2c) . We found the level of c-Kit proteins in Prl2 +/+ cells expressing NOTCH1-ICN1 was significantly higher than that of the Prl2 Figures S2e and f) . Further, treatment of some human T-ALL cells with γ-secretase inhibitor (GSI) decreased the level of PRL2 proteins (Supplementary Figure S2g) . Thus, our data suggest that oncogenic NOTCH1 may promote T-ALL development through sustaining PRL2 and c-Kit expression.
To date, very little information exists in the literature on the role of PRL2 in human T-ALL. 5, 6 In this study, we have identified a critical role for PRL2 phosphatase in the proliferation and survival of human T-ALL cells. Further, we demonstrated that PRL2 is important for the leukemogenic potential of oncogenic NOTCH1 in vivo. Our findings suggest that pharmacological inhibition of PRL2 holds potential as a novel therapy for T-cell acute lymphoblastic leukemia, and might also be applicable to the treatment of other human cancers.
